Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04458532
Other study ID # 20-130
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date October 8, 2020
Est. completion date July 2025

Study information

Verified date April 2024
Source Memorial Sloan Kettering Cancer Center
Contact Jessica Scott, PhD
Phone 646-888-8103
Email scottj1@mskcc.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will compare the effects on cardiorespiratory fitness (CRF) of aerobic exercise in different amounts (number of minutes/session) over different periods of time (number of weeks). Aerobic exercise is physical activity of light-to-moderate intensity that uses the large muscle groups (muscles in your legs, buttocks, back, and chest) and can be performed for at least 10 minutes. The researchers will study the effects of different exercise programs on how well the study participants' bodies use oxygen, how well their heart pumps blood, how well their lungs function, and how healthy their blood vessels are.


Description:

Prior to the initiation of every supervised aerobic training session, patient resting vital signs will be assessed to ensure the patient can safely proceed with the session. Vital signs, including resting heart rate and blood pressure, will be collected and monitored per ExOnc program guidelines. In addition, the planned session will not be initiated if the ExOnc staff member observes any concerns that may compromise participant safety and/or the integrity of the planned session. Vital sign monitoring guidelines for unsupervised sessions, prescribed at lower intensities, will be advised by the exercise physiologist at the time the session plan is provided to the patient. Patients will be instructed to not begin an unsupervised session if their resting heart rate or blood pressure is outside the recommended guidelines.


Recruitment information / eligibility

Status Recruiting
Enrollment 152
Est. completion date July 2025
Est. primary completion date July 2025
Accepts healthy volunteers No
Gender Female
Age group 21 Years to 80 Years
Eligibility Inclusion Criteria: - Aged 21-80 years - Female - Surgically resected early stage (I-III) primary breast cancer - Post-menopausal, defined as one of the following: - Age = 45 with no menses for at least 2 years - Chemically and/or surgically induced menopause through ovarian suppression, as determined by the primary oncologist - Estradiol level of =30 pg/mL - An interval of at least one year, but no more than five years, following the full completion of definitive therapy for malignant disease. Definitive therapy is defined as: - Surgery plus radiation - Surgery plus chemotherapy - Surgery plus trastuzumab - Exercise intolerance (i.e., patients must have a VO2peak below the predicted for active age and sex-matched individuals. (+/- the technical error of 1.32 mL/kg/min)]. Note: Normative values are available up to 80 years of age) - Able to complete an acceptable baseline CPET, in the absence of high-risk ECG findings or other inappropriate response to exercise as determined by the PI, as defined by any of the following criteria: - Achieving a plateau in oxygen consumption, concurrent with an increase in power output; - A respiratory exchange ratio = 1.10; - Attainment of maximal predicted heart rate (HRmax) (i.e., within 10 bpm of age-predicted HRmax [HRmax = 220-Age[years]); - Volitional exhaustion, as measured by a rating of perceived exertion (RPE) = 18 on the BORG scale - Willingness to comply with all study-related procedures. Exclusion Criteria: - Any of the following absolute contraindications to cardiopulmonary exercise testing: - Acute myocardial infarction within 3-5 days of any planned study procedures - Unstable angina - Uncontrolled arrhythmia causing symptoms or hemodynamic compromise - Recurrent syncope - Active endocarditis - Acute myocarditis or pericarditis - Symptomatic severe aortic stenosis - Uncontrolled heart failure - Acute pulmonary embolus or pulmonary infarction within 3 months of any planned study procedures - Thrombosis of lower extremities - Suspected dissecting aneurysm - Uncontrolled asthma - Pulmonary edema - Respiratory failure - Acute non-cardiopulmonary disorders that may affect exercise performance or be aggravated by exercise (e.g., infection, renal failure, thyrotoxicosis) - Presence of any other concurrent, actively treated malignancy - History of any other malignancy treated within the past 3 years (other than non-melanoma skin cancer) - Presence of distant metastatic disease (i.e., stage IV) - Room air desaturation at rest = 85% - Mental impairment leading to inability to cooperate. - Any other condition or intercurrent illness that, in the opinion of the investigator, makes the participant a poor candidate for the trial.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Aerobic Training
300 min/wk for 16 weeks
Aerobic Training
150 min/wk for 32 weeks
Aerobic Training
300 min/wk for 32 weeks
Aerobic Training
150 min/wk for 16 weeks

Locations

Country Name City State
United States Hartford Healthcare Cancer Institute @ Hartford Hospital (Data Collection Only) Hartford Connecticut
United States Memorial Sloan Kettering Cancer Center New York New York

Sponsors (2)

Lead Sponsor Collaborator
Memorial Sloan Kettering Cancer Center National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary peak oxygen consumption (VO2peak; ml O2.kg-1.min) response rate A CRF change =1.32 ml O2.kg-1.min-1 will be considered a response; a change <1.32 ml O2.kg-1.min-1 will be considered a non-response. 32 weeks
See also
  Status Clinical Trial Phase
Completed NCT02816112 - Granulocyte-colony Stimulating Factors or Antibiotics for Primary Prophylaxis for Febrile Neutropenia Phase 4
Completed NCT02816164 - A Study to Compare Administration Schedules of G-CSF (Filgrastim) for Primary Prophylaxis of Febrile Neutropenia Phase 4
Completed NCT03946683 - Cyberknife for Early Stage Breast Cancer N/A
Completed NCT01162200 - Cyberknife® Partial Breast Irradiation (PBI) for Early Stage Breast Cancer Phase 1
Completed NCT01965522 - Anti-proliferative Effects of Vitamin D and Melatonin in Breast Cancer Phase 2
Completed NCT00309569 - Randomized Study Comparing Pre- and Postoperative vs. Conventional Adjuvant Treatment in Receptor-negative Patients Phase 3
Terminated NCT01545648 - Pilot Study to Evaluate the Impact of Denosumab on Disseminated Tumor Cells (DTC) in Patients With Early Stage Breast Cancer Phase 2
Completed NCT02428114 - A Multi Centre Study to Determine the Feasibility of Using an Integrated Consent Model to Compare Standard of Care Administration Schedules of G-CSF (Filgrastim) for Primary Prophylaxis of Chemotherapy-Induced Febrile Neutropenia in Early Stage Breast Cancer (React-G Study) N/A
Active, not recruiting NCT02685332 - Phase I Dose Escalation of Single Fraction Adjuvant Stereotactic Body Partial Breast Irradiation Early Stage Breast CA Phase 1
Completed NCT02159157 - A Randomized, Controlled Trial to Determine the Effects of an Exercise Intervention on Physical Activity During Chemotherapy for Patients With Early Stage Breast Cancer N/A
Completed NCT01871116 - POWER-remote Weight Loss Program in Early Stage Breast Cancer N/A
Terminated NCT01166581 - Impact of Breast Magnetic Resonance Imaging (MRI) on Mastectomy Rates N/A
Recruiting NCT06311357 - Percent Weight Change in the Medical Supplement Group of Early Breast Cancer N/A
Terminated NCT02364960 - Targeted Intraoperative Therapy Registry at Bethesda North Hospital (TARGIT)
Active, not recruiting NCT03561454 - A Registry of Intra-Operative Radiation Therapy (IORT) Using the Xoft ® Axxent ® eBx ™ System Patients
Completed NCT02485678 - A Pragmatic Trial of Ambulatory Toxicity Management in Patients Receiving Adjuvant or Neo-adjuvant Chemotherapy for Early Stage Breast Cancer N/A
Active, not recruiting NCT02297672 - Partial Breast Irradiation Using Interstitial Permanent Palladium-103 Seed Implant N/A
Completed NCT02335671 - Evaluating Mass Spectrometry And Intraoperative MRI In The Advanced Multimodality Image Guided Operating Suite (Amigo) In Breast-Conserving Therapy N/A
Completed NCT03102307 - Registry Trial to Evaluate the Clinical Utilization of Targeted Axillary Dissection (TAD)
Recruiting NCT04607473 - ABUS for Early-stage Breast Cancer N/A